Results 201 to 210 of about 8,825,337 (378)
MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NFκB axis
Molecular Oncology, EarlyView.mir‐196a promotes Esophagus Adenocarcinoma aggressiveness. On one hand, mir‐196a targets the valosin‐containing protein (VCP) mRNA, causing the accumulation of c‐MYC protein that leads to high amounts of TERT. On the other hand, mir‐196a targets the inhibitor of NFκB (NFKBIA).Jesús García‐Castillo, Carlos M. Martínez‐Cáceres, Manuel Bernabé‐García, Vicente Munitiz, David Ruiz de Angulo, Pascual Parrilla, Ángeles Ortiz, Luisa F. Martínez de Haro, María L. Cayuela +8 morewiley +1 more sourceThe anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer
Molecular Oncology, EarlyView.The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect Cécilia Thomine, Sterenn Guillemot, Louis‐Bastien Weiswald, Romane Florent, Edwige Abeilard, Florence Giffard, Emilie Brotin, Mélanie Briand, Enora Dolivet, Laurent Poulain, Marie Villedieu +10 morewiley +1 more sourceComprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi +11 morewiley +1 more sourceCirculating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman +17 morewiley +1 more sourceTrans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Nature Genetics, 2021 D. Conti, B. Darst, Lilit C Moss, E. Saunders, Xin Sheng, Alisha Chou, F. Schumacher, A. Olama, S. Benlloch, Tokhir Dadaev, M. Brook, A. Sahimi, T. Hoffmann, Atushi Takahashi, K. Matsuda, Y. Momozawa, Masashi Fujita, K. Muir, A. Lophatananon, Peggy Wan, L. Le Marchand, L. Wilkens, V. Stevens, S. Gapstur, B. Carter, J. Schleutker, T. Tammela, C. Sipeky, A. Auvinen, G. Giles, M. Southey, R. MacInnis, C. Cybulski, D. Wokołorczyk, J. Lubiński, D. Neal, J. Donovan, F. Hamdy, Richard M. Martin, B. Nordestgaard, S. F. Nielsen, Maren Weischer, S. Bojesen, M. Røder, P. Iversen, J. Batra, S. Chambers, Leire Moya, L. Horvath, J. Clements, W. Tilley, G. Risbridger, H. Gronberg, M. Aly, R. Szulkin, M. Eklund, T. Nordström, N. Pashayan, A. Dunning, M. Ghoussaini, R. Travis, T. Key, E. Riboli, Jong Y. Park, T. Sellers, Hui-Yi Lin, D. Albanes, S. Weinstein, L. Mucci, E. Giovannucci, S. Lindstrom, P. Kraft, D. Hunter, K. Penney, Constance Turman, C. Tangen, P. Goodman, I. Thompson, R. Hamilton, N. Fleshner, A. Finelli, M. Parent, J. Stanford, E. Ostrander, M. Geybels, Stella Koutros, L. Freeman, M. Stampfer, A. Wolk, N. Håkansson, G. Andriole, R. Hoover, M. Machiela, K. D. Sørensen, M. Borre, W. Blot, W. Zheng, E. Yeboah, J. Mensah, Yong-jie Lu, Hong-wei Zhang, Ninghan Feng, Xueying Mao, Yudong Wu, Shan-Chao Zhao, Zan Sun, S. Thibodeau, S. McDonnell, D. Schaid, C. West, N. Burnet, G. Barnett, C. Maier, T. Schnoeller, Manuel Luedeke, A. Kibel, B. Drake, O. Cussenot, G. Cancel-Tassin, F. Menegaux, Thérèse Truong, Y. Koudou, E. John, E. Grindedal, L. Maehle, K. Khaw, S. Ingles, M. Stern, A. Vega, A. Gómez-Caamaño, L. Fachal, B. Rosenstein, S. Kerns, H. Ostrer, M. Teixeira, P. Paulo, Andreia Brandão, S. Watya, Alex Lubwama, J. Bensen, E. Fontham, J. Mohler, Jack A. Taylor, M. Kogevinas, J. Llorca, G. Castaño‐Vinyals, L. Cannon-Albright, C. Teerlink, C. Huff, S. Strom, L. Multigner, P. Blanchet, L. Brureau, R. Kaneva, C. Slavov, V. Mitev, R. Leach, Brandi Weaver, H. Brenner, Katarina Ćuk, B. Holleczek, K. Saum, E. Klein, A. Hsing, R. Kittles, Adam B. Murphy, C. Logothetis, Jeri Kim, S. Neuhausen, L. Steele, Y. Ding, W. Isaacs, B. Nemesure, A. Hennis, J. Carpten, H. Pandha, A. Michael, K. De Ruyck, G. De Meerleer, P. Ost, Jianfeng Xu, A. Razack, Jasmine Lim, S. Teo, Lisa F. Newcomb, D. Lin, J. Fowke, C. Neslund-Dudas, B. Rybicki, M. Gamulin, D. Lessel, T. Kuliš, N. Usmani, S. Singhal, M. Parliament, F. Claessens, S. Joniau, T. Van den Broeck, M. Gago-Domínguez, J. Castelao, M. Martínez, Samantha E. T. Larkin, P. Townsend, Claire Aukim-Hastie, W. Bush, M. Aldrich, D. Crawford, S. Srivastava, J. Cullen, G. Petrovics, G. Casey, M. Roobol, G. Jenster, R. V. van Schaik, Jennifer J. Hu, M. Sanderson, R. Varma, R. Mckean-Cowdin, M. Torres, Nicholas Mancuso, S. Berndt, S. K. Van Den Eeden, D. Easton, S. Chanock, M. Cook, F. Wiklund, H. Nakagawa, J. Witte, R. Eeles, Z. Kote-Jarai, C. Haiman +230 moresemanticscholar +1 more sourceDose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment
Molecular Oncology, EarlyView.Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin +10 morewiley +1 more source
